PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
7.06%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
10.36%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
28.30%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
28.30%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
24.68%
Share count expansion well above AGEN's 0.70%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above AGEN's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
OCF growth above 1.5x AGEN's 4.51%. David Dodd would confirm a clear edge in underlying cash generation.
17.79%
FCF growth above 1.5x AGEN's 4.45%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3628.66%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
45.61%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
-15204.15%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
97.68%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
59.13%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
9892.41%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
293.35%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
201.29%
Positive short-term equity growth while AGEN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
64.49%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
13.21%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-38.56%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.